AIH

Shares of Aesthetic Medical Intl (NASDAQ:AIH) moved higher by 3.1% in pre-market trading after the company reported Q3 results.Quarterly Results Earnings per share came in at $(0.04) down from $(0.02) yera-over-year.Revenue of $41,434,000 higher by 24.49% year over year, which beat the estimate of $37,960,000.Looking Ahead Earnings guidance hasn't been issued by the company for now.Revenue guidance hasn't been issued by the company for now.How To Listen To The Conference Call Date: Nov 30, 2020View more earnings on AIHTime: 08:00 AMET Webcast URL: https://78449.choruscall.com/dataconf/productusers/aih/mediaframe/42130/indexr.htmlTechnicals Company's 52-week high was at $10.6652-week low: $3.81Price action over last quarter: Up 40.94%Company Description Aesthetic Medical International Holdings Group Ltd provides aesthetic medical services in China. The company generates revenue from three service offerings: non- surgical aesthetic medical services, comprising minimally invasive aesthetic treatments and energy-based treatments; surgical aesthetic medical services, and general healthcare services and other aesthetic medical services. Most of the firm's revenue gets derived from Non-surgical aesthetic medical services. Geographically, it derives revenue from China.See more from Benzinga * Click here for options trades from Benzinga * Earnings Scheduled For November 30, 2020(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Aesthetic Medical Intl (NASDAQ:AIH) reported quarterly losses of $(0.04) per share. This is a 100 percent decrease over losses of $(0.02) per share from the same period last year. The company reported quarterly sales of

Aesthetic Medical International (AIH): Q3 GAAP EPS of -$0.04.Revenue of $41.43M (+24.4% Y/Y) beats by $4.79M.Press Release

Shenzhen, China, Oct. 22, 2020 (GLOBE NEWSWIRE) -- Aesthetic Medical International Holdings Group Limited (the “Company” or Nasdaq: AIH), a leading provider of aesthetic medical services in China, today announces it has entered into a strategic cooperation agreement (the “Agreement”) with Chengdu Meb Network Technology Co., Ltd. (“Meb”), a leading social community platform in China connecting consumers, professionals and medical institutions in the aesthetics medical industry. Pursuant to the Agreement, the Company will become a member of Meb’s multi-channel network, allowing more consumers on Meb’s platform to have access to the Company’s services. Meb will provide various marketing services to the Company, including providing marketing trainings to the Company’s staff, allowing the Company to use Meb’s online promotional tools, and optimizing the operation of the Company’s social media platforms.Dr. Zhou Pengwu, the Chairman and CEO of the Company, commented, “We are excited about signing the Agreement with Meb. Meb and we share the same core value: bringing beauty, health and confidence to our customers through our services. This move marks an in-depth collaboration between the Company and Meb, and enables us to work together to provide high quality services to our customers, and to build and maintain a benign environment in the aesthetics medical industry in China.”About Aesthetic Medical International Holdings Group LimitedAIH, known as “Peng’ai” in China, is a leading provider of aesthetic medical services in China. AIH operates through treatment centers that spread across major cities in mainland China, and also has presence in Hong Kong and Singapore. Leveraging over 20 years of clinical experience, AIH provides one-stop aesthetic service offerings, including surgical aesthetic treatments, non-surgical aesthetic treatments, and general medical services and other aesthetic services. According to certain third party industry consultant, AIH was the third-largest private aesthetic medical services provider in China in terms of revenue in 2018. For more information regarding the Company, please visit: http://ir.aihgroup.net/.Safe Harbor StatementThis press release contains “forward-looking statements.” These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “aims,” “future,” “intends,” “plans,” “believes,” “estimates,” “likely to” and similar statements. Statements that are not historical facts, including statements about the Company’s beliefs, plans and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. These risks and uncertainties and others that relate to the Company’s business and financial condition are detailed from time to time in the Company’s SEC filings, and could cause the actual results to differ materially from those contained in any forward-looking statement. These forward-looking statements are made only as of the date indicated, and the Company undertakes no obligation to update or revise the information contained in any forward-looking statements, except as required under applicable law.Investor Relations ContactFor investor and media inquiries, please contact:Aesthetic Medical International Holdings Group LimitedEmail: ir@pengai.com.cnAscent Investor Relations LLCMs. Tina XiaoTel: (917) 609-0333Email: tina.xiao@ascent-ir.com

Aesthetic Medical International ([[AIH]]) BOD authorizes a share repurchase program of up to $6M worth of its ADS over the next 12-month period, effective until October 12, 2021.The company expects to

Shenzhen, China, Oct. 13, 2020 (GLOBE NEWSWIRE) -- Aesthetic Medical International Holdings Group Limited (the “Company”) (NASDAQ: AIH), a leading provider of aesthetic medical services in China, today announced that its board of directors has authorized a share repurchase program under which the Company may repurchase up to US$6.0 million worth of its American depositary shares over the next 12-month period, effective until October 12, 2021, pursuant and subject to applicable laws and the Company’s securities trading policy. All factors, including, but not limited to, trading price, trading volume and general market conditions, along with the Company’s working capital requirements and general business conditions shall be taken into account when determining the timing, volume and conditions of the share repurchases under the share repurchase program. The Company’s share repurchases may be made from time to time in the open market at prevailing market prices, depending on market conditions and in accordance with the applicable rules and regulations. The Company’s board of directors will review the share repurchase program periodically and may authorize adjustments to its terms and size or suspend or discontinue the share repurchase program. The Company expects to utilize its existing funds to fund repurchases made under this program.About Aesthetic Medical International Holdings Group LimitedAIH, known as “Peng’ai” in China, is a leading provider of aesthetic medical services in China. AIH operates through treatment centers that spread across major cities in mainland China, and also has presence in Hong Kong and Singapore. Leveraging over 20 years of clinical experience, AIH provides one-stop aesthetic service offerings, including surgical aesthetic treatments, non-surgical aesthetic treatments, and general medical services and other aesthetic services. According to certain third party industry consultant, AIH was the third-largest private aesthetic medical services provider in China in terms of revenue in 2018. For more information regarding the Company, please visit: http://ir.aihgroup.net/.Safe Harbor StatementThis press release contains “forward-looking statements.” These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “aims,” “future,” “intends,” “plans,” “believes,” “estimates,” “likely to” and similar statements. Statements that are not historical facts, including statements about the Company’s beliefs, plans and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. These risks and uncertainties and others that relate to the Company’s business and financial condition are detailed from time to time in the Company’s SEC filings, and could cause the actual results to differ materially from those contained in any forward-looking statement. These forward-looking statements are made only as of the date indicated, and the Company undertakes no obligation to update or revise the information contained in any forward-looking statements, except as required under applicable law.Investor Relations ContactFor investor and media inquiries, please contact:Aesthetic Medical International Holdings Group LimitedEmail: ir@pengai.com.cnAscent Investor Relations LLCMs. Tina XiaoTel: (917) 609-0333Email: tina.xiao@ascent-ir.com

Shenzhen, China, Sept. 25, 2020 (GLOBE NEWSWIRE) -- Aesthetic Medical International Holdings Group Limited (the “Company” or Nasdaq: AIH), a leading provider of aesthetic medical services in China, today announces its unaudited financial results for the second quarter ended June 30, 2020. Dr. Zhou Pengwu

Aesthetic Medical International (AIH): Q2 GAAP EPS of -$0.10.Revenue of $23.6M (decrease of 21.4% Y/Y) beats by $2.7M.Press Release